Vanda Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 203
- Market Cap
- $311.8M
- Introduction
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The ...
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT04326426
- Locations
- 🇺🇸
Lenox Hill Hospital Northwell Health, New York, New York, United States
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT04140695
- Locations
- 🇺🇸
Vanda Investigational Site, Spokane, Washington, United States
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT04127058
- Locations
- 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT04028492
- Locations
- 🇺🇸
Vanda Investigational Site, Salt Lake City, Utah, United States
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT03838926
- Locations
- 🇺🇸
Vanda Investigational Site, Seattle, Washington, United States
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT03772340
- Locations
- 🇺🇸
Vanda Investigational Site, Santa Monica, California, United States
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 375
- Registration Number
- NCT03568331
- Locations
- 🇺🇸
Vanda Investigational Site, Spokane, Washington, United States
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT03373201
- Locations
- 🇺🇸
Vanda Investigational Site, Houston, Texas, United States
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT03291041
- Locations
- 🇺🇸
Vanda Investigational Site, Chevy Chase, Maryland, United States
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
- Conditions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT03154697
- Locations
- 🇺🇸
Vanda Pharmaceuticals, Washington, District of Columbia, United States